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Background: As it is often difficult for a transplant pathologist to make a definite diagnosis of acute cellular
rejection (ACR) by routine morphological analysis of liver allograft biopsy, supplementary methods and objective
markers are needed to facilitate this determination.
Methods: To evaluate the diagnostic value of cytotoxic molecules in ACR episodes, immunohistochemical staining
for perforin, granzyme B and T-cell intracellular antigen-1 (TIA-1) were performed in liver allograft biopsies. The
positive cells in the portal tract area and lobules were counted separately to investigate the distribution of the
cytotoxic molecules.
Results: The immunohistochemical study showed that the overall positive rates for the three markers were not
significantly different between the ACR and non-ACR groups. However, in the portal tract area, perforin-,
granzyme B- and TIA-1-positive cells in the ACR group were significantly more than those in the non-ACR
groups. In the lobules, perforin- and granzyme B-positive cells in the ACR group were significantly more than
those in the biliary complication and opportunistic infection groups, while TIA-1-positive cells was significantly
fewer than those in non-ACR groups. The numbers of positive cells in the portal tract area correlated with the
rejection activity index of ACR.
Conclusions: These results indicate that, though the overall positive rates have nonsense in ACR diagnosis, the
quantification and local distribution analysis of cytotoxic molecule positive cells in liver tissue is helpful for
differential diagnosis and severity evaluation of ACR following liver transplantation.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/2292255038100487
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With the incidence reportedly ranging from 30% to 70%,
acute cellular rejection (ACR) is one of the most com-
mon complications after orthotopic liver transplantation
(OLT) [1,2]. The appropriate immunosuppressive ther-
apy for ACR, which is important for reducing morbidity
and improving the life quality of recipients, is based on
precise diagnoses and grading. At present, the Banff
schema is accepted as the diagnostic judge standard for
ACR, which is morphologically characterized by lympho-
cyte infiltration of portal tracts, bile duct damage and
endothelitis in portal and hepatic central veins [3-5].
However, due to the overlapping histological features be-
tween ACR and other complications following liver
transplantation, differential diagnoses and severity eva-
luations for ACR are often difficult. This prompted us to
look for some potential methods and molecular markers
helpful for diagnosing ACR and evaluating its severity.
It is generally accepted that T cell-mediated immune
reactions play a pivotal role in the pathogenesis of ACR,
and CD8+ cytotoxic T cells induce target cell death during
acute allograft rejection in liver allograft tissues [6-8].
Cytotoxic molecules such as perforin, granzyme B and T-
cell intracellular antigen-1 (TIA-1) are present in the cyto-
plasmic granules of cytotoxic T cells and function at the
effector end of the acute rejection process [9]. Neverthe-
less, a study also showed that cytotoxic molecules can also
mediate liver graft rejection in the absence of CD8+ T cells
[10]. Thus, cytotoxic protein detection might be a sensitive
and objective method for predicting acute rejection injury.
It has been reported that granzyme B and perforin played
predictive roles in acute rejection diagnosis after renal,
heart and intestinal transplantation [11-14]. Moreover, in
acute rejection after kidney transplantation, the quantity
and intensity of TIA-1 expression are both increased, and
this variation can reflect rejection severity to some extent
[15]. However, the diagnostic value of these cytotoxic
molecules in acute cellular rejection after liver transplant-
ation has not yet been clearly elucidated.
To further evaluate the role of cytotoxic molecules in
ACR diagnosis, immunohistological staining of perforin,Table 1 Underlying diseases of the transplant recipients









Primary biliary cirrhosis 2
Primary hepatic amyloidosis 2granzyme B and TIA-1 was performed on allograft liver
biopsies. As it was noted that different liver diseases
mainly target at different tissues and cells of liver, the
positive cells in the portal tract area and lobules were
counted separately to investigate the local distribution
characteristics of the cytotoxic molecules. Meanwhile,
correlations between the numbers of positive cells and
the Banff rejection activity index (RAI) were analyzed.
Materials and methods
Patients and clinic materials
The liver tissue samples were obtained from the Institute
of Hepatobiliary Surgery of Southwest Hospital, the Third
Military Medical University. Written informed consent
was obtained from all patients and this study was carried
out in accordance with the principles of the Helsinki
Declaration and approved by the Ethical Committee of
the Third Military Medical University, Chongqing, Peoples
Republic of China.
Between February 2000 and December 2006, 234 sam-
ples were obtained by percutaneous needle biopsy from
patients that underwent orthotopic liver transplantation
(OLT) in Southwest hospital. A total of 108 biopsy sam-
ples from 73 patients (66 males and 7 females) were en-
rolled in the study based on the following criteria: those
with more than 10 portal tracts in each biopsy; those
with integrated clinical follow-up information. The ages
of the patients ranged from 18 to 69 years and their pri-
mary clinical diagnoses are listed in Table 1.
All patients enrolled in the study were treated with
glucocorticoid, Mycophenolate Mofetil and cyclosporine
A or tacrolimus after surgery. Glucocorticoid was stopped
within three months, and cyclosporine A or tacrolimus
was administered separately to maintain immunosuppres-
sion. Complications were diagnosed based on clinical and
biochemical data in combination with pathological evalu-
ation of allograft liver needle biopsy specimens. ACR epi-
sodes were generally treated with daily administration of
methylprednisolone (20mg/kg) for three consecutive days.
Histological observation
Biopsy specimens were fixed in 10% buffered formalin,
embedded in paraffin, sectioned serially at a 4μm thick-
ness, and de-waxed. H&E was performed routinely. The
RAI for each specimen was scored according to the Banff
consensus by two independent qualified transplant pathol-
ogists unaware of the clinical data of the patients [3].
Immunohistological staining
Monoclonal antibodies against perforin, granzyme B
(DAKO, Glostrup, Denmark) and TIA-1 (abcam,
Cambridge, UK.) were applied to the above sections.
Antigens were retrieved in citrate buffer in a microwave
oven and endogenous peroxidase activity was blocked
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bated at 4°C with primary antibodies (with a dilution of
1:200 for perforin, 1:200 for granzyme B and 1:100 for
TIA-1) overnight and the Envision™ staining (DAKO,
Glostrup, Denmark) procedure was performed. Sections
with the primary antibody application omitted served as a
negative control.
Brown granular staining was considered to be a posi-
tive signal for the IHC assay. The positive cells were
counted under light microscope according to the previ-
ous description with some modifications [8]. The posi-
tive cells in the portal tract area and lobules were
counted separately to investigate the distribution of the
cytotoxic molecules. For each slide, the positive cells in
least 10 portal tracts and 10 high power fields (HPF) in
the lobules were counted under the light microscope
(Olympus BX51, Japan). The average positive cells per
portal tract and per HPF in the lobules were calculated.
Statistical analysis
Statistical analyses were performed using SPSS Version
13.0 for Windows (Statistical Package for the Social
Sciences; SPSS, Munich, Germany). Groups were com-
pared using Mann-Whitney U-tests, and Spearman’s
Rank test was performed to look for correlations be-
tween the number of positive cells and RAI score.
P<0.05 was considered statistically significant.
Results
Histological observation
In the 108 cases, 62 cases were diagnosed as ACR and
46 were non-ACR, including 19 biliary complications
(BC), 6 ischemic/reperfusion injuries (I/R), 6 opportunis-
tic infections (OI) and 15 undefined complications (UD).Figure 1 The histopathological features of acute cellular rejection. Ty
duct inflammation/damage and venous endotheliatis, so called “triads,” app
rejection (H&E, ×200).In the ACR cases, varying degrees of lymphocytic infil-
tration of portal tracts, bile duct damage and suben-
dothelialitis were recognized in the pathologically
examined specimens. The numbers of samples with RAI
scores of 1, 2, 3, 4, 5, 6, 7 and 8 were 4, 9, 9, 15, 9, 6, 6
and 4 cases respectively. (Figure 1A-B).The expression and distribution of cytotoxic effector
molecules in ACR and non-ACR tissue
Perforin, granzyme B and TIA-1 were mainly located in
the cytoplasm of inflammatory cells in portal tracts and
lobules, and they were frequently observed in the epithe-
lia of interlobular bile ducts and subendothelial portions
of portal veins in ACR, (Figure 2 and 3). There was no
significant difference in the positive rates for perforin,
granzyme B and TIA-1 between ACR and non-ACR
samples (98.4%% versus 95.6%, 96.8% versus 91.3% and
100% versus 100%, respectively). However, the number
and distribution of positive cells were different. There
were significantly more perforin-, granzyme B- and TIA-
1-positive cells in the portal tract area in the ACR group
than in the non-ACR groups, and there was no signifi-
cant difference among the non-ACR groups. The num-
bers of perforin- and granzyme B-positive cells in
lobules in the ACR group were significantly greater than
those in the BC, OI and UD groups, but they were simi-
lar to that in the I/R group. The numbers of TIA-1-
positive cells in lobules in the ACR group was signifi-
cantly lower than those in BC, I/R and OI groups, but
was similar to that in UD group. (Figure 4) The above
results indicate that the positive cell number, but not the
positive rate of cytotoxic molecules in liver biopsies,
could be used as a statistical indicator of ACR.pical histopathological changes, including portal inflammation, bile
eared in mild (A, RAI = 4) and moderate (B, RAI = 7) acute cellular
Figure 2 Immunostaining features of perforin, granzyme B and TIA-1 in the portal tract area. The expression of perforin (A), granzyme B
(B) and TIA-1 (C) in the portal tract area in biopsies without ACR is sporadic and significantly less than that with ACR (D, E and F, respectively).
(Immunostaining with hematoxylin counter staining, ×200).
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In the ACR group, we recognized a tendency for the
number of positive cells to increase as the RAI score
rose, so the relationship between the number of positive
cells and RAI score was further analyzed. There were a
significant positive correlations between the numbers of
positive cells in portal tracts and the RAI scores
(r=0.829 for perforin, 0.799 for granzyme B and 0.780
for TIA-1, respectively), (Figure 5). The numbers of
positive cells in lobules were not correlated with the RAI
score (p>0.05). These results indicate that immunohisto-
chemical analysis of cytotoxic molecules in the portal
tract area of liver might be a useful supplementary tool
for the objective evaluation of ACR severity.
Discussion
Acute cellular rejection (ACR) is still common after liver
transplantation (OLT) despite well developed immuno-
suppressive agents, with incidence ranging from 30% to
70% in different series. Multivariate analysis showed that
recipient age, underlying liver disease, and Child’s class
before LT were independently associated with thedevelopment of ACR [16]. Although the pathogenesis of
ACR remains need to be further elucidated, it is gener-
ally accepted that ACR occurrence is mainly due to
recognition of donor alloantigen by recipient T lympho-
cytes. Following recognition and activation, T lympho-
cytes trigger a series of immunoresponses and effect
mechanisms. In most cases, ACR responds well to im-
munosuppressive treatment. However, this should not
lead to an underestimation of its importance because
immunosuppressive treatment is associated with
increased risk for infections, recurrence of virus hepa-
titis, and metabolic complications such as diabetes melli-
tus, hyperlipidemia, and hypertension, etc. On the other
hand, the repeated ACR episodes without immunosup-
pressive treatment or with inadequate immunosuppres-
sive therapy might induce the occurrence of chronic
rejection which would result in graft loss. So appropriate
immunosuppressive therapy for ACR, is critical for redu-
cing morbidity and improving the life quality of recipi-
ents, and makes it necessary to diagnose ACR timely
and definitely.
Berman et al. summarized the histopathologic features
of ACR in three aspects which constitute the basis of
Figure 3 Immunostaining features of perforin, granzyme B and TIA-1 in lobules. The expression of perforin (A) and granzyme B (B) in
lobules of biopsies without ACR is sporadic and significantly less than that with ACR (D and E, respectively). However, the expression of TIA-1 in
lobules of biopsies without ACR (C) is prevalent, more than that with ACR (F). (Immunostaining with hematoxylin counter staining, ×400).
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including mainly mononuclear cells and also various
amounts of neutrophils and eosinophils, in the portal
area; 2) endothelialitis in portal and hepatic central veins
characterized by subendothelial infiltration of inflamma-
tory cells; and 3) bile duct damage with cholangitis and
degenerative necrosis of biliary epithelial cells. At
present, allograft biopsy remains the ‘gold standard’ for
diagnosing ACR, and the Banff schema is accepted by
pathologists as the diagnosing and grading criterion for
ACR. However, there are overlapping histological fea-
tures and clinical manifestation between ACR and other
complications following liver transplantation [17], such
as ischemic/reperfusion injury, biliary complication, re-
current virus hepatitis, etc. These overlaps make ACR
diagnosis and grading often difficult, and urge us to ex-
plore some potential methods and molecular markers
helpful for diagnosing ACR and evaluating its severity.
Perforin and granzyme B are proteins in the cytoplas-
mic granules of T lymphocytes and natural killer cells.
Upon release by exocytosis, perforin disrupts lipid mem-
branes and granzyme B accesses the cytosol of target
cells, subsequently triggering cell death throughapoptosis [18,19]. Animal experiments and clinical stud-
ies found that perforin and granzyme B were overex-
pressed after liver transplantation, which suggested a
role in pathogenesis of acute rejection [20,21]. Studies
have reported that perforin and granzyme B can be sen-
sitive and specific markers for diagnosing ACR [22,23].
Inconsistent with these reports, in our cohort, perforin
and granzyme B were expressed widely in liver allograft
biopsies with or without ACR, and no difference in ex-
pression rate was observed. This inconsistence may arise
from differences in the examination methods and judg-
ing criteria. Because of the non-utility of the positive rate
for ACR diagnosis, in current study, we focused on
quantifying the positive cells and determining their dis-
tribution in liver tissue. Our results showed that the
numbers of perforin- and granzyme B-positive cells in
the portal tract area were significantly greater with ACR
than with other complications. However, in the lobule
area, there were more positive cells with ACR than with
BC or OP, but a similar amount of cells to that with I/R
injury. These results are consistent with reports stating
that ACR involves not only damage to the portal tract
but also lobule injury, and that the cytotoxic T cells are
Figure 4 The numbers of perforin-, granzyme B- and TIA-1-positive cells in liver biopsies after liver transplantation. The numbers of
perforin- and granzyme B-positive cells in the portal tract area in the ACR group were greater than in the non-ACR groups (A, B), while in lobules
there were more positive cells in the ACR group than in the BC, OI and UD groups, but a similar amount to that in the I/R group (D, E). There
were significantly more TIA-1-positive cells in the portal tract area in the ACR group than in the non-ACR groups (C), but in lobules there were
significantly fewer in the ACR group than in the BC, I/R or OI groups (F). ACR, acute cellular rejection; BC, biliary complications; I/R, ischemic/
reperfusion injury; OI, opportunistic infection; UD, undefined complications. *P<0.01, #P<0.05, compared with ACR.
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cates that the quantification of perforin- and granzyme
B-positive cells in different areas in liver biopsies could
be more informative for ACR diagnosis than mere deter-
mination of the positive rate.Figure 5 Correlations between perforin-, granzyme B- and TIA-1-posi
each sample are plotted in each column (A, B and C, respectively).Unlike perforin and granzyme B, which are expressed
in cytotoxic T cells and NK cells, TIA-1, also named
granule membrane protein-17 (GMP-17), is expressed
not only by cytotoxic T cells and NK cells but also by
monocytes and neutrophils [26,27]. TIA-1 is the granuletive cells in the portal tract area and the RAI scores. Values for
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and apoptosis in cytolytic lymphocyte targets. In acute
rejection after kidney transplantation, the quantity and
intensity of TIA-1 expression increase, and the degree of
this variation can reflect rejection severity to some ex-
tent [15,28,29]. However, the diagnostic value of TIA-1
in acute rejection after liver transplantation has not been
determined. Our data show that TIA-1 is also expressed
widely in liver allograft biopsies with or without ACR.
Interestingly, our results showed that the number of
TIA-1-positive cells significantly increased in the portal
tract area but not in lobules during ACR episodes. By
contrast, during other complications such as biliary
complications, opportunistic infections, and preserva-
tion/reperfusion injuries, TIA-1-positive cells signifi-
cantly increased in lobules but not in the portal tract
area. These opposite alterations may occur because cyto-
toxic T cells are prevalent in the portal tract in ACR
cases, while monocytes and neutrophils, which also re-
lease TIA-1, are more popular in lobular in biliary com-
plications, opportunistic infections, and preservation/
reperfusion injuries. This distributional difference of
TIA-1-positive cells implies that a marked increase in
the portal tract combined with insignificant changes in
lobules may indicate a diagnosis of ACR. To our know-
ledge, no previous studies found this pattern of TIA-1
expression in liver grafts. Therefore, the local distribu-
tion of TIA-1-positive cells in liver biopsies may provide
a morphological means of distinguishing ACR from
other complications after liver transplantation.
One study showed that the number of CD8-positive
cells correlated with rejection severity in liver allograft
tissues.8 However, the relationship between rejection se-
verity and the expression of perforin, granzyme B and
TIA-1 has not been determined. Our present data show
that the numbers of perforin-, granzyme B- and TIA-1-
positive cells in the portal tract area correlated with
acute rejection severity after liver transplantation. This
result is compatible with the notion that the portal tracts
are the main targets of ACR and that these cytotoxic
molecules are at the effector end of the acute rejection
process. Based on our results, we conclude that the
identification of perforin, granzyme B and TIA-1 in the
portal tract area of liver biopsies would be helpful for
determining the severity of ACR.
Immunohistochemical staining has become a routine
method in clinical pathological diagnosis. Immunohisto-
chemical assays for perforin, granzyme B and TIA-1 are
applicable in most pathology laboratories of large hospi-
tals. ACR pathological diagnoses are based on H&E find-
ings, according to the Banff schema. Our result raise the
possibility that immunohistochemical analysis of cyto-
toxic molecules has the potential to become a supple-
mentary as well as an objective assessment method forACR diagnosis to be used as an adjunct to the Banff
schema in the future.
In conclusion, our results indicate that, though the
overall positive rates have nonsense in ACR diagnosis,
the quantification and local distribution analysis of cyto-
toxic molecule positive cells in liver tissue is helpful for
differential diagnosis and severity evaluation of ACR fol-
lowing liver transplantation.
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